TrialVaccine2022

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.

Sonia Pérez-Rodríguez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.